You are here : Home > The Institute > News > Proteomic analysis of SARS-CoV-2 infected cells

News | Virus | Mass spectrometry | Proteomics

Proteomic analysis of SARS-CoV-2 infected cells


​In order to optimize the amplification of quality inactivated virus, for the manufacture of a vaccine, a team from SPI (CEA Marcoule) used mass spectrometry to analyze the dynamics of the proteome of SARS-CoV-2 infected cells, at two multiplicities of infection. With more than 3,220 identified host proteins, researchers are also starting to decipher the processes and cellular networks impacted by this virus.

Published on 6 July 2020

Abstract

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and continues to spread quickly around the globe. Currently, no effective vaccine is available to prevent COVID-19 and an intense global development activity is in progress. In this context, the different technology platforms face several challenges resulting from the involvement of a new virus still not fully characterised. Finding of the right conditions for virus amplification for the development of vaccines based on inactivated or attenuated whole viral particles is among them.
In the present study, scientists of SPI (CEA Marcoule) describe the establishment of a workflow based on shotgun tandem mass spectrometry data to guide the optimisation of the conditions for viral amplification. In parallel, they analysed the dynamic of the host cell proteome following SARS-CoV-2 infection providing a global overview of biological processes modulated by the virus and that could be further explored to identify drug targets to address the pandemic.

Schematic representation of the experimental design


Top page